Mechanism of B7-H3-Targeted ADCs Explained: Target Recognition, Internalization, Payload Release and the Bystander Effect

With the continuous advancement of antibody-drug conjugate (ADC) technology, B7-H3-targeted ADCs are rapidly emerging as a major research focus in targeted cancer therapy. B7-H3 (CD276) is overexpressed in a wide range of solid tumors while showing relatively low expression in normal tissues, making it an attractive target for precision drug delivery. Dengyue Pharma provides a systematic overview of the mechanism of action of B7-H3-targeted ADCs, including molecular design advantages and current clinical development trends.

What Is B7-H3? A Key Molecule in Tumor Immune Regulation

B7-H3 belongs to the B7 family of immune regulatory molecules and is a transmembrane glycoprotein involved in immune modulation and tumor microenvironment regulation. Studies have shown that B7-H3 can suppress T-cell activation and promote tumor immune evasion, thereby facilitating tumor progression and metastasis.

⭐ Key characteristics of aberrant B7-H3 expression include:

● High expression in lung cancer, prostate cancer, breast cancer, and neuroblastoma

● Association with increased tumor aggressiveness and poor prognosis

● Involvement in tumor angiogenesis and metabolic regulation

● Potential impact on sensitivity to immune checkpoint therapies

These biological features have established B7-H3 as a promising next-generation anticancer target and laid the foundation for research into the mechanism of B7-H3-targeted ADCs.

Structural Components of B7-H3-Targeted ADCs

An ADC typically consists of three essential components:

1️⃣ A targeting monoclonal antibody

2️⃣ A chemical linker

3️⃣ A cytotoxic payload

In B7-H3-targeted ADCs, the antibody specifically recognizes the B7-H3 antigen on tumor cells, enabling precise localization and minimizing damage to normal tissues.

⭐ Common payload categories include:

● Microtubule inhibitors (e.g., MMAE-based agents)

● DNA-damaging drugs (e.g., topoisomerase inhibitors)

● Novel high-potency cytotoxic toxins

The structural design of ADCs determines both therapeutic efficacy and safety, providing the basis for understanding their subsequent pharmacological mechanisms.

Core Mechanisms of Action of B7-H3-Targeted ADCs

1️⃣ Target Recognition and Binding

After systemic administration, the antibody component selectively binds to B7-H3 expressed on tumor cell surfaces, enabling highly specific tumor targeting. This step represents the initial phase of the mechanism of B7-H3-targeted ADCs.

2️⃣ Receptor-Mediated Internalization

Following antigen binding, the ADC–B7-H3 complex is internalized into tumor cells through receptor-mediated endocytosis and transported to lysosomal compartments, creating favorable conditions for drug release.

3️⃣ Linker Cleavage and Payload Release

Within the acidic or protease-rich lysosomal environment, the linker is cleaved, releasing the cytotoxic payload.

⭐ Released payloads may exert antitumor effects by:

● Inhibiting microtubule polymerization

● Inducing DNA damage

● Arresting the cell cycle

● Triggering apoptotic cell death

4️⃣ Bystander Effect

Some payloads are membrane-permeable and can diffuse into neighboring tumor cells, including those with low or heterogeneous B7-H3 expression. This “bystander effect” enhances overall antitumor efficacy and helps overcome tumor heterogeneity.

Potential Therapeutic Advantages of B7-H3-Targeted ADCs

⭐ Compared with conventional chemotherapy or naked monoclonal antibodies:

● Precision drug delivery reduces systemic toxicity

● Improved efficacy against heterogeneous tumors

● Potential for combination with immunotherapy

● Possibility of overcoming certain resistance mechanisms

Moreover, B7-H3 expression in tumor vasculature and cancer stem-like cells suggests that B7-H3-targeted ADCs may provide multi-layered antitumor activity.

Clinical Development and Future Trends

Multiple B7-H3 ADC candidates are currently under clinical investigation worldwide, with indications including:

● Small cell lung cancer

● Neuroblastoma

● Prostate cancer

● Triple-negative breast cancer

Future development directions include:

⭐ Bispecific ADC designs

⭐ Tunable and next-generation linker technologies

⭐ Treatment strategies for low-expression patient populations

⭐ Combination approaches with PD-1/PD-L1 immunotherapies

As precision oncology continues to evolve, deeper insights into the mechanism of B7-H3-targeted ADCs are expected to drive the development of next-generation anticancer treatment paradigms.

Conclusion

Overall, B7-H3 represents a novel dual-function target involved in both immune regulation and tumor progression, offering an ideal platform for ADC-based therapies. Through mechanisms such as selective target recognition, intracellular payload release, and the bystander effect, B7-H3-targeted ADCs are emerging as an important innovation in solid tumor treatment. With ongoing clinical validation and advances in molecular engineering, this strategy holds strong potential to further improve patient outcomes and advance the era of precision oncology.